| 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) F Cardoso, S Paluch-Shimon, E Senkus, G Curigliano, MS Aapro, F André, ... Annals of Oncology 31 (12), 1623-1649, 2020 | 1028 | 2020 |
| Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised … SA Hurvitz, F Andre, Z Jiang, Z Shao, MS Mano, SP Neciosup, LM Tseng, ... The Lancet Oncology 16 (7), 816-829, 2015 | 326 | 2015 |
| Breast cancer classification according to immunohistochemistry markers: subtypes and association with clinicopathologic variables in a peruvian hospital database CS Vallejos, HL Gómez, WR Cruz, JA Pinto, RR Dyer, R Velarde, ... Clinical breast cancer 10 (4), 294-300, 2010 | 277 | 2010 |
| ConCerv: a prospective trial of conservative surgery for low-risk early-stage cervical cancer KM Schmeler, R Pareja, AL Blanco, JH Fregnani, A Lopes, M Perrotta, ... International Journal of Gynecologic Cancer 31 (10), 2021 | 99 | 2021 |
| In silico evaluation of DNA Damage Inducible Transcript 4 gene (DDIT4) as prognostic biomarker in several malignancies JA Pinto, C Rolfo, LE Raez, A Prado, JM Araujo, L Bravo, W Fajardo, ... Scientific reports 7 (1), 1526, 2017 | 70 | 2017 |
| The impact of educational materials on compliance and persistence rates with adjuvant aromatase inhibitor treatment: first-year results from the compliance of aromatase … P Neven, C Markopoulos, M Tanner, M Marty, R Kreienberg, L Atkins, ... The Breast 23 (4), 393-399, 2014 | 63 | 2014 |
| Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study … J Gligorov, B Ataseven, M Verrill, M De Laurentiis, KH Jung, HA Azim, ... European Journal of Cancer 82, 237-246, 2017 | 51 | 2017 |
| The implementation of the Plan Esperanza and response to the imPACT Review T Vidaurre, C Santos, H Gómez, G Sarria, E Amorin, M López, ... The Lancet Oncology 18 (10), e595-e606, 2017 | 47 | 2017 |
| Early detection of gastric cancer using global, genome-wide and IRF4, ELMO1, CLIP4 and MSC DNA methylation in endoscopic biopsies F Pirini, S Noazin, MH Jahuira-Arias, S Rodriguez-Torres, L Friess, ... Oncotarget 8 (24), 38501, 2017 | 47 | 2017 |
| A phase I/II trial of the safety and clinical activity of a HER2-protein based immunotherapeutic for treating women with HER2-positive metastatic breast cancer G Curigliano, G Romieu, M Campone, T Dorval, L Duck, JL Canon, ... Breast cancer research and treatment 156, 301-310, 2016 | 42 | 2016 |
| Human epidermal growth factor receptor 2–positive breast cancer is associated with indigenous American ancestry in Latin American women KM Marker, VA Zavala, T Vidaurre, PC Lott, JN Vásquez, ... Cancer research 80 (9), 1893-1901, 2020 | 31 | 2020 |
| Does patient education work in breast cancer? Final results from the global CARIATIDE study C Markopoulos, P Neven, M Tanner, M Marty, R Kreienberg, L Atkins, ... Future Oncology 11 (2), 205-217, 2015 | 30 | 2015 |
| Impact of the delayed initiation of adjuvant chemotherapy in the outcome of triple negative breast cancer Z Morante, R Ruiz, JM Araujo, JA Pinto, G de la Cruz-Ku, ... Clinical Breast Cancer 21 (3), 239-246. e4, 2021 | 29 | 2021 |
| PIK3CA mutations in Peruvian patients with HER2-amplified and triple negative non-metastatic breast cancers CA Castaneda, M Lopez-Ilasaca, JA Pinto, M Chirinos-Arias, F Doimi, ... Hematology/oncology and stem cell therapy 7 (4), 142-148, 2014 | 28 | 2014 |
| Prognostic effect of hormone receptor status in early HER2 positive breast cancer patients HL Gómez, CA Castañeda, CE Vigil, T Vidaurre, RG Velarde, WR Cruz, ... Hematology/oncology and stem cell therapy 3 (3), 109-115, 2010 | 24 | 2010 |
| A phase II randomized study of lapatinib combined with capecitabine, vinorelbine, or gemcitabine in patients with HER2-positive metastatic breast cancer with progression after … HL Gómez, S Neciosup, C Tosello, M Mano, J Bines, G Ismael, PX Santi, ... Clinical breast cancer 16 (1), 38-44, 2016 | 23 | 2016 |
| Immunotherapy in triple-negative breast cancer: A literature review and new advances GA Valencia, P Rioja, Z Morante, R Ruiz, H Fuentes, CA Castaneda, ... World Journal of Clinical Oncology 13 (3), 219, 2022 | 21 | 2022 |
| Patterns of mutation enrichment in metastatic triple-negative breast cancer CH Saravia, C Flores, LJ Schwarz, L Bravo, J Zavaleta, J Araujo, ... Clinical Medicine Insights: Oncology 13, 1179554919868482, 2019 | 21 | 2019 |
| Triple-negative breast cancer in Peru: 2000 patients and 15 years of experience G De-la-Cruz-Ku, M Luyo, Z Morante, D Enriquez, MG Möller, ... PloS one 15 (8), e0237811, 2020 | 18 | 2020 |
| Prostate cancer in Latin America: challenges and recommendations RB Reis, A Alías-Melgar, A Martínez-Cornelio, SP Neciosup, JP Sade, ... Cancer Control 27 (1), 1073274820915720, 2020 | 18 | 2020 |
